Anticoagulation trends in adults aged 65 and over with atrial fibrillation; a cohort study

Data and Population

Data were extracted from the Clinical Practice Research Datalink (CPRD), a primary care research database of anonymised, electronic coded records from the Vision computer system. ⁹ All clinical activity (including diagnoses and prescribing) in primary care are recorded using clinical codes. The data-set upon which these analyses were performed was originally extracted to explore the impact of case finding for atrial fibrillation at the time of influenza vaccination. Influenza vaccination is offered to everyone over the age of 65 in the UK, and uptake in this age group over the time period of the study was 71-75%¹⁰.

Patients included in this study were registered with a GP in England, had records which fulfilled CPRD data quality standards⁹, had a first diagnosis of AF between 01/09/2008 and 31/08/2018, and attended at least one influenza vaccine after the age of 65 and during the study period, with at least one year’s registration before their first eligible flu vaccination. For each patient follow up started at the date of first recorded AF diagnosis and ended when the patient left the GP practice or died, the practice stopped contributing data to CPRD, or 31/08/2018, whichever was earliest. Further limited exclusions for data quality were made; patients with an AF diagnosis recorded more than 30 days after the end of follow up were excluded. Details of patient selection, inclusion and exclusion criteria are given in figure 1.

• Download figure
• Open in new tab

Figure 1: Patient flow diagram

*UTS: Up to standard. CPRD defined criteria for data quality. ⁹ TOD: Transfer out Date. Date at which patients transfers to another practice.

Definitions of AF and anticoagulation

We analysed cases of AF diagnosed each year from 2008/09 to 2017/18 (1st September – 31 August).

The date and type of first anticoagulation are defined at the first record of an oral anticoagulant prescription. For all analyses we defined an anticoagulation prescription as a medication from the prespecified list (appendix 1) with a tablet quantity greater than zero.

Lists of codes which record AF diagnoses and anticoagulation prescribing available in supplementary data, appendix 1.

Demographic and clinical characteristics

We defined three age groups, 65-74, 75-84 and 85+. People aged 85 and over were grouped because of small numbers and the risk of statistical disclosure. We described the clinical characteristics of the study population on the day before AF diagnosis as the count of long term conditions (out of the 20 included in the Cambridge multi morbidity score). ¹¹ Deprivation was defined as the index of multiple deprivation (IMD) score of the GP practice attended by each cohort member, linked and provided by CPRD.

Analyses

In our first analysis we explored changes in the proportion of people with AF prescribed anticoagulation by age and year. Each cohort was defined by age group at diagnosis and 2 year diagnosis interval. Patients were included in the denominator of each 2 year time point analysis if they had contributed data at any point during the 2 year time interval and were defined as anticoagulated if they had received any prescription of anticoagulation in this time.

For our second analysis we included incident AF cases who received anticoagulation within 365 days of diagnosis and calculated the proportion, with 95% confidence intervals, of these, stratified by age group, who received a DOAC as the first prescription after AF diagnosis. For this analysis patients contributed to both the numerator and denominator of any year if they had a minimum of 365 days of follow up after AF diagnosis.

In our final analyses we described the time to end of anticoagulation use, stratified by age group at diagnosis and by age and type of anticoagulation. Analysis entry point was defined as the later of AF diagnosis date or first anticoagulation prescription date. The date of end of anticoagulation is defined as the date of the last anticoagulation prescription if this is greater than 90 days before leaving the sample. If the patient left the sample for any reason within 90 days of anticoagulation prescription they were censored at the leaving date. For this analysis type of anticoagulation was defined as one of four categories; Warfarin only, DOAC only, Warfarin changed to DOAC during follow up and DOAC changed to Warfarin. Patients with a prescription for a vitamin K antagonist other than Warfarin were excluded due to small numbers. The survivor function was calculated, with 95% confidence intervals, at the 5 year time point for all age and medication cohorts.

All data analysis was completed using STATA software v.16. ¹² There was no patient or public involvement in this project.

Summary

Anticoagulation has increased across all age groups from 2008-2018 with the greatest rise in those aged over 85. There have been both cohort and period effects with regard to prescription of anticoagulation. Increases are greatest in those with newly diagnosed AF. DOACs now represent the vast majority of anticoagulant prescriptions offered to all patients aged over 65 with newly diagnosed AF. Anticoagulation persistence decreases with age, being lowest in those aged over 85. Persistence is higher in those prescribed DOACs as compared to warfarin.

Strengths and Limitations

The major strength of this study is the large sample size and generalisability to the UK population. Ours is the first study to tease out period from cohort effects in anticoagulation prescribing in this age group. As with all electronic record studies a major limitation is the reliance on recorded, coded, diagnoses. It is possible that patients receiving anticoagulation are more likely to have a coded diagnosis of atrial fibrillation and therefore the incidence of anticoagulation seen in this paper may be artificially elevated. Inclusion of only patients who have had an influenza vaccination may mean that the cohort of patients described in this study are those more likely to attend for healthcare and therefore more likely to receive anticoagulation. However the AF incidence seen is comparable to that reported using all CPRD records. ¹³ These potential biases are unlikely to have had any major effect on the observed trends, since their magnitude will not have changed substantially over the time period of the study.

A further limitation is the use of anticoagulant prescription issues as a marker for persistence with medication. It is possible that prescriptions are issued without medication being taken, particularly considering the move toward electronic repeat dispensing in the UK.

We have shown that anticoagulation goes up over time in all age groups. This is likely in part due to increase use of anticoagulation but may also represent differential survival in those who are anticoagulated.

Comparison with existing literature

The trends in overall anticoagulation and the use of DOAC as the anticoagulant of choice we present are consistent with previous UK studies. ^4,14 Our work brings these results up to date and presents new data with regard to age stratification for those aged over 65.

We show that people who were started on a DOAC tend to persist longer than those on warfarin, however there may be both patient selection and time effects. DOACs were initiated in later years than warfarin and there has been, over the period of the study, increased knowledge and awareness of the importance of persisting with anticoagulation. What we have observed is similar to the persistence seen in a recent meta-analysis where pooled persistence with DOACs was higher than vitamin K antagonists (OR 1.44), ¹⁵ although many of the studies included within this have a significantly shorter period of follow up. Anticoagulation persistence is known to be lower in younger age groups^16,17, our patients were older, mean age 80 years, than in any of the studies included in the systematic review and this may partially explain the high overall persistence seen. In clinical trials where randomisation eliminates patient selection bias there was no clear pattern of superiority of DOAC over Warfarin. ^18-20 Our study is observational and therefore we cannot be sure of the effects of patient selection bias. The choice of anticoagulant is largely an individual decision made between clinician and patient and there may be an unmeasured characteristic that affects the choice of medication and the likelihood of persistence.

Implications for research policy and practice

Our results show there has been a major shift in the use of anticoagulation in the UK. DOACs have become the first line anticoagulant for those with AF and are being used in ever increasing numbers of patients, including large numbers aged over 85. We provide some circumstantial evidence to support the success of initiatives to increase uptake of anticoagulation. ²¹ This suggests that poor uptake of anticoagulation is no longer a barrier to screening for atrial fibrillation.

We note that the high levels of anticoagulant prescribing that we observed are against a background of multi-morbidity, which would be expected to increase the potential iatrogenic effects of anticoagulation prescribing, as multi-morbidity increases risk of haemorrhage. ²²

Those prescribed warfarin require frequent monitoring and dose adjustment. Currently there are multiple models of care as to how this service is provided, across both primary and secondary care. As the number of patients receiving warfarin continues to decline consideration will need to be given to the best model of care for continuation of specialist warfarin services for the small number of patients who continue to use it. This will need to account for the likely older age profile of these patients.

A final consideration is that the current data are all drawn prior to the COVID-19 pandemic. As a result of the pandemic, UK guidance, endorsed by the Royal College of General Practitioners, has encouraged the accelerated switching of warfarin to DOAC for patients with AF to avoid unnecessary trips to health care settings for monitoring. ²³ Pandemic guidance from NHS England explicitly recommends that patients newly diagnosed with AF are offered a DOAC in preference to Warfarin. Therefore the trends seen in this paper may well have accelerated in 2020.